Toshiya Nishi
Ovid Therapeutics (United States)(US)Takeda (Japan)(JP)
Publications by Year
Research Areas
Cholesterol and Lipid Metabolism, Hormonal Regulation and Hypertension, Steroid Chemistry and Biochemistry, Drug Transport and Resistance Mechanisms, Receptor Mechanisms and Signaling
Most-Cited Works
- → Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice(2020)75 cited
- → Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice(2021)61 cited
- → Analysis of Binding Sites for the New Small-Molecule CCR5 Antagonist TAK-220 on Human CCR5(2005)61 cited
- → Decreased expression of signaling lymphocytic-activation molecule-associated protein (SAP) transcripts in T cells from patients with rheumatoid arthritis(2001)46 cited
- → Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H)(2021)45 cited
- → Preferential enhancement of GluN2B-containing native NMDA receptors by the endogenous modulator 24S-hydroxycholesterol in hippocampal neurons(2018)38 cited
- → Anticonvulsive properties of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor(2022)36 cited
- → Functional Interaction between the Transcription Factor Krüppel-like Factor 5 and Poly(ADP-ribose) Polymerase-1 in Cardiovascular Apoptosis(2007)31 cited
- → Short rib-polydactyly syndrome, Majewski type, in two male siblings(1979)31 cited
- → Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy(2022)19 cited